SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Wants More Data Before Approving Clinical Cell Culture Ltd.'s ReCell

January 16, 2006 | 
1 min read
Tissue engineering specialist Clinical Cell Culture's (ASX:CCE, C3) share price took a blow today, in the wake of a request by the US Food and Drug Administration (FDA) for more performance data before it can approve C3's ReCell for sale in the US.
Regulatory Australia
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Silhouette of a business person on the top of a mountain peak in sunset background. Winner and conquer of businessman concept.
Approvals
Denali Delivers ‘Welcome Positive’ for Rare Disease Space With FDA’s Hunter Syndrome Nod
March 26, 2026
 · 
3 min read
 · 
Tristan Manalac
Podcast
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
March 25, 2026
 · 
1 min read
 · 
Heather McKenzie
Adults hand drawing pathway for baby boy. Parent influence on child development and future. Parental control and support for growth and education of kid. vector
FDA
Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug
March 24, 2026
 · 
3 min read
 · 
Heather McKenzie
Focal seizure. Vector illustration of human brain and electroencephalograhy or EEG originating from temporal lobe.
Parkinson’s disease
FDA Warns of Seizure Risk With Some Parkinson’s Drugs
March 23, 2026
 · 
2 min read
 · 
Tristan Manalac